The Lamellar Ichthyosis market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Lamellar Ichthyosis: An Overview
Lamellar Ichthyosis (LI) is a rare genetic disorder, where skin cells are produced at a normal rate, but they do not separate normally at the surface of the outermost layer of skin and are not shed as quickly as they should be which lead to the formation of scale. As per the Ichthyosis Support Group (2020), Lamellar Ichthyosis cannot be diagnosed prenatally. It is important that Lamellar Ichthyosis is considered in any persistently red baby to avoid misdiagnosis or incorrect treatment.
Lamellar Ichthyosis Market Key Facts
-
As per the study by Dreyfus et al. (2014), the reported prevalence of Lamellar Ichthyosis was estimated to be around 4.5 in a million; this was the first study to explore the prevalence of inherited Ichthyosis in France.
-
It is estimated that about 2/3rd of the patients suffered from moderate to severe illness.
-
The total prevalent population of Lamellar Ichthyosis in the 7MM was 4,038 in 2017.
-
According to DelveInsight analysis, in the genetic mutation-specific cases of Lamellar Ichthyosis for 7MM, most of the cases are found with TGM1 mutation. It is estimated that about 1,817 cases with TGM1 mutation were estimated for the year 2017, during the study period (2017–2030).
-
Among the European 5 countries, Germany had the highest diagnosed prevalent population of Lamellar Ichthyosis with 222 cases in 2017, followed by France and the United Kingdom. On the other hand, Spain had the lowest diagnosed prevalent population of Lamellar Ichthyosis, i.e., 135 cases in 2017.
-
As per DelveInsight, Japan accounts for 16% of the 7MM patient population of Lamellar Ichthyosis in 2017.
Get FREE sample copy at: Lamellar Ichthyosis Therapeutics Market
Key Benefits of Lamellar Ichthyosis Market Report
-
The report provides an in-depth analysis of Lamellar Ichthyosis Market Size and Share till 2030 in the seven major markets.
-
The report will help in developing business strategies by understanding the Lamellar Ichthyosis Market Trends, key players, and ongoing developments that shape and drive market growth in the upcoming years.
-
It covers Lamellar Ichthyosis’s current treatment practices, emerging drugs, market share of the individual therapies in the 7MM.
-
The report provides a detailed assessment of the Lamellar Ichthyosis market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.
As per DelveInsight, the market size of Lamellar Ichthyosis in the 7MM was found to be USD 3.9 million in 2017.
The Lamellar Ichthyosis market size is anticipated to increase in the coming years, owing to the expected entry of premium price assets, development of gene therapies for the treatment of Lamellar Ichthyosis, increase in awareness among the physicians, and better diagnostic tools such as biomarkers for the early stage of the disease.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Lamellar Ichthyosis market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Lamellar Ichthyosis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Lamellar Ichthyosis Market Drivers
-
Development of Gene Therapies
-
Less Competitive Therapeutic Landscape
-
Improvement in the Diagnosis
Lamellar Ichthyosis Epidemiology
The epidemiology section covers insights about the historical and current Lamellar Ichthyosis patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Epidemiology Segmentation
-
Total Prevalent Cases
-
Genetic Mutation-specific Cases
-
Total Diagnosed Prevalent Cases
-
Severity-Specific Diagnosed Prevalent Cases
-
Total Treated Cases of Lamellar Ichthyosis
Lamellar Ichthyosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Lamellar Ichthyosis market or expected to get launched in the market during the study period. The analysis covers Lamellar Ichthyosis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Lamellar Ichthyosis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Lamellar Ichthyosis Therapeutics Market
There are very limited options of medications that can be used to treat Ichthyosis. At the present time, there is no cure available to treat Ichthyosis and the current options are only off-label therapies like emollients, keratolytics, and retinoids are used for symptomatic treatment.
The dynamics of the Lamellar Ichthyosis market is anticipated to change in the coming years owing to the rise in numbers of company’s taking interest in the development of drugs for Lamellar Ichthyosis, improvement in the diagnosis, expected launch of emerging therapies during the forecast period of 2020─2030.
Key Companies in the Lamellar Ichthyosis Market includes
-
Galderma
-
Mayne Pharma
-
Krystal Biotech
-
Timber Pharmaceuticals
And several others
Lamellar Ichthyosis Therapies covered in the report includes:
-
Trifarotene (CD5789)
-
TMB-001
-
KB105
And many more.
Request for Sample @ Lamellar Ichthyosis Emerging Therapies and Key Companies
Table of Content
1. Key Insights
2. Executive Summary
3. Lamellar Ichthyosis Competitive Intelligence Analysis
4. Lamellar Ichthyosis Market Overview at a Glance
5. Lamellar Ichthyosis Disease Background and Overview
6. Lamellar Ichthyosis Patient Journey
7. Lamellar Ichthyosis Epidemiology and Patient Population
8. Lamellar Ichthyosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Lamellar Ichthyosis Unmet Needs
10. Key Endpoints of Lamellar Ichthyosis Treatment
11. Lamellar Ichthyosis Marketed Products
12. Lamellar Ichthyosis Emerging Therapies
13. Lamellar Ichthyosis Seven Major Market Analysis
14. Attribute Analysis
15. Lamellar Ichthyosis Market Outlook (7 major markets)
16. Lamellar Ichthyosis Access and Reimbursement Overview
17. KOL Views on the Lamellar Ichthyosis Market.
18. Lamellar Ichthyosis Market Drivers
19. Lamellar Ichthyosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/lamellar-ichthyosis-market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/